FDA rejects Alnylam's heart disease treatment over insufficient data

KristofferTripplaar/SipaUSA/APTheFoodandDrugAdministrationrejectedanAlnylamPharmaceuticals’therapyfo ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022




focus

author：hotspot    Page View：368

Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET.

STAT’s reporters, strung-out from several days of ASCO madness, will take the virtual stage to share convention hall insights, predictions for the months ahead, and of course will take your audience questions live.

advertisement

Sponsor Introduction

  • Ashwin Athri, EVP, strategy, innovation, & partnerships, Precision AQ

Featured Speakers

  • Angus Chen, cancer reporter, STAT
  • Adam Feuerstein, senior writer, biotech, STAT
  • Matthew Herper, senior writer, medicine; editorial director of events, STAT
  • Katherine MacPhail, programmer, editorial events, STAT (moderator)

Sponsored By

Previous article： Was Amgen transparent enough on FDA's concern on cancer drug?
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection